Direxion Daily Financial Bull 3X Shares ETF
FAS
SPDR S&P Metals & Mining ETF
XME
Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
4
Ultra Financials Proshares
UYG
5
Ishares Trust U.S. Aerospace & Defense Etf
ITA
US Stock MarketDetailed Quotes
NeuroSense Therapeutics (NRSN)
- 0.8000
- -0.0175-2.14%
Close Dec 26 16:00 ET
- 0.8000
- 0.00000.00%
Post 16:10 ET
23.76MMarket Cap-2.22P/E (TTM)
0.8400High0.7700Low255.55KVolume0.8300Open0.8175Prev Close205.38KTurnover1.37%Turnover RatioLossP/E (Static)29.70MShares2.600052wk High-47.06P/B14.94MFloat Cap0.763252wk Low--Dividend TTM18.67MShs Float8.1800Historical High--Div Yield TTM8.56%Range %0.4000Historical Low0.8030Avg Price1Lot Size
NRSN Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
NRSN Orderflow
Unit: --
NRSN Orderflow Trend
IntradayDayWeekMonth
No Data
NeuroSense Therapeutics (NRSN) News
Neurosense Stock Rises as Alzheimer's Drug Shows Favorable Safety Profile
Express News | Neurosense Confirms Favorable Safety and Tolerability of Primec in an Alzheimer's Phase 2 Study
$NRSN Q3 2025 Earnings Preview: Recent $NRSN Insider Trading, Hedge Fund Activity, and More
Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight
Noble Financial Maintains NeuroSense Therapeutics(NRSN.US) With Buy Rating, Maintains Target Price $9
Noble Financial Remains a Buy on Neurosense Therapeutics Ltd. (NRSN)
NeuroSense Therapeutics (NRSN) Stock Forum
$NeuroSense Therapeutics (NRSN.US)$
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
NeuroSense_Therapeutics_Logo
NEWS PROVIDED BY
NeuroSense
Dec 22, 2025, 09:17 ET
Clinical and Biomarker Outcomes Expected to Be Reported in Q1 2026
CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative disease...
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
NeuroSense_Therapeutics_Logo
NEWS PROVIDED BY
NeuroSense
Dec 22, 2025, 09:17 ET
Clinical and Biomarker Outcomes Expected to Be Reported in Q1 2026
CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative disease...
1
1
$NeuroSense Therapeutics (NRSN.US)$ NeuroSense Therapeutics Resumes Regulatory Push in Canada for ALS Drug PrimeC After Productive Talks
Benzinga
2m
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that following a productive discussion with Health Canada ("Agency"), the Company is resuming its regulatory advancement in Canada for PrimeC in amyotrophic later...
Benzinga
2m
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that following a productive discussion with Health Canada ("Agency"), the Company is resuming its regulatory advancement in Canada for PrimeC in amyotrophic later...
1
$NeuroSense Therapeutics (NRSN.US)$ tomorrow 1.70 good news on Prime C
1
1
$NeuroSense Therapeutics (NRSN.US)$ no chatter here? this has almost half its volume of yesterday already after 30min
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)
JACK454 : why they keep driving prices down I think no matter what they accomplish they are going to always keep it at 1 dollar. they will just add millions of shares they have proven that they don’t care about the investors